KALA BIO, Inc. financial data

Symbol
KALA on Nasdaq
Industry
Pharmaceutical Preparations
Location
1167 Massachusetts Avenue, Arlington, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Kala Pharmaceuticals, Inc. (to 6/23/2023)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 337 % -32.7%
Quick Ratio 13.4 % -56.2%
Debt-to-equity 547 % +80.5%
Return On Equity -449 % -71.9%
Return On Assets -69.4 % -7.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.61M shares +71.2%
Common Stock, Shares, Outstanding 4.61M shares +71.2%
Entity Public Float 34.1M USD +68.8%
Common Stock, Value, Issued 5K USD +66.7%
Weighted Average Number of Shares Outstanding, Basic 4.63M shares +81.5%
Weighted Average Number of Shares Outstanding, Diluted 4.63M shares +81.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.17M USD -6.95%
General and Administrative Expense 4.4M USD -11.1%
Operating Income (Loss) -41.1M USD -2.1%
Nonoperating Income (Expense) 2.18M USD +1690%
Net Income (Loss) Attributable to Parent -39M USD +16.1%
Earnings Per Share, Basic -11.9 USD/shares +47.3%
Earnings Per Share, Diluted -1.93 USD/shares +43.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 49.2M USD -12.2%
Accounts Receivable, after Allowance for Credit Loss, Current 195K USD -98.7%
Inventory, Net 0 USD -100%
Assets, Current 51.3M USD -11.4%
Property, Plant and Equipment, Net 762K USD -4.99%
Operating Lease, Right-of-Use Asset 1.78M USD -15.4%
Assets 54.1M USD -11.5%
Accounts Payable, Current 711K USD -9.66%
Employee-related Liabilities, Current 775K USD -72.2%
Accrued Liabilities, Current 4.5M USD -28.2%
Liabilities, Current 23.9M USD +132%
Operating Lease, Liability, Noncurrent 1.53M USD -18.5%
Liabilities 47.2M USD -5.37%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1K USD
Retained Earnings (Accumulated Deficit) -660M USD -6.28%
Stockholders' Equity Attributable to Parent 6.86M USD -38.9%
Liabilities and Equity 54.1M USD -11.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.8M USD -12%
Net Cash Provided by (Used in) Financing Activities 8.44M USD +195%
Net Cash Provided by (Used in) Investing Activities -13K USD +88%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 4.61M shares +71.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.42M USD +65.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.14M USD -6.76%
Deferred Tax Assets, Valuation Allowance 129M USD +6.03%
Deferred Tax Assets, Gross 129M USD +6.56%
Operating Lease, Liability 1.9M USD -13.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -39M USD +16.1%
Property, Plant and Equipment, Gross 1.86M USD +14.7%
Operating Lease, Liability, Current 368K USD +13.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 622K USD +3.49%
Lessee, Operating Lease, Liability, to be Paid, Year One 601K USD +3.44%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 555K USD -32.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 644K USD +3.54%
Deferred Tax Assets, Operating Loss Carryforwards 109M USD +6.2%
Preferred Stock, Shares Authorized 5M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 440K USD -31.7%
Operating Lease, Payments 575K USD +710%
Additional Paid in Capital 667M USD +5.47%
Preferred Stock, Shares Outstanding 53.1K shares
Depreciation, Depletion and Amortization 66K USD -14.3%
Share-based Payment Arrangement, Expense 8.67M USD +43.3%
Interest Expense 5.8M USD -13.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares